Daniel Arumi Selected Research

fesoterodine

2/2019	Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?
10/2017	Characteristics of antimuscarinic responders versus suboptimal responders in a randomized clinical trial of patients with overactive bladder symptoms.
1/2017	A pooled analysis of the efficacy of fesoterodine for the treatment of overactive bladder, and the relationship between safety, co-morbidity and polypharmacy in patients aged 65 years or older.
6/2015	Factors associated with dose escalation of fesoterodine for treatment of overactive bladder in people >65 years of age: A post hoc analysis of data from the SOFIA study.
6/2015	Fesoterodine clinical efficacy and safety for the treatment of overactive bladder in relation to patient profiles: a systematic review.
2/2015	Review of the efficacy and safety of fesoterodine for treating overactive bladder and urgency urinary incontinence in elderly patients.
10/2013	Effects of drug cessation after flexible-dose fesoterodine in patients with overactive bladder.
5/2011	Cost-effectiveness analysis of antimuscarinics in the treatment of patients with overactive bladder in Spain: a decision-tree model.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Daniel Arumi Research Topics

Disease

9	Overactive Urinary Bladder (Overactive Bladder) 02/2019 - 05/2011
3	Urinary Incontinence 02/2019 - 02/2015
2	Constipation 02/2019 - 06/2015
1	Neoplasms (Cancer) 01/2022
1	Venous Thromboembolism 01/2022
1	Urge Urinary Incontinence (Urge Incontinence) 06/2015
1	Urinary Retention 02/2015
1	Urinary Tract Infections (Urinary Tract Infection) 05/2011
1	Infections 05/2011

Drug/Important Bio-Agent (IBA)

8	fesoterodine FDA Link 02/2019 - 05/2011
5	Muscarinic AntagonistsIBA 10/2017 - 05/2011
1	Factor Xa InhibitorsIBA 01/2022
1	edoxabanIBA 01/2022
1	RivaroxabanIBA 01/2022
1	AnticoagulantsIBA 01/2022
1	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA 01/2022
1	apixabanIBA 01/2022
1	Tolterodine Tartrate (Detrol)FDA Link 10/2017
1	Pharmaceutical PreparationsIBA 10/2013

Therapy/Procedure

1	Polypharmacy 01/2017
1	Therapeutics 06/2015
1	Home Nursing (Nursing, Home) 05/2011
1	Incontinence Pads 05/2011